Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results-Reference-Cited by-同舟云学术

Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results

Published:2019-07 Issue:7 Volume:25 Page:1347-1354
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Chamoun Kamal,Milton Denái R.,Ledesma Celina,Young Ken H.,Jabbour Elias J.,Alatrash Gheath,Anderlini Paolo,Bashir Qaiser,Ciurea Stefan O.^ORCID,Marin David,Molldrem Jeffrey J.^ORCID,Olson Amanda L.^ORCID,Oran Betul^ORCID,Popat Uday R.,Rondon Gabriela,Champlin Richard E.^ORCID,Gulbis Alison M.,Khouri Issa F.

Funder

National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference40 articles.

1. Reduced mortality after allogeneic hematopoietic-cell transplantation;Gooley;N Engl J Med,2010

2. Nonmyeloablative allogeneic stem cell transplantation for non-Hodgkin lymphoma;Khouri;Cancer J,2012

3. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies;Khouri;J Clin Oncol,1998

4. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab;Khouri;Blood,2008

5. Acute graft-versus-host disease—biologic process, prevention, and therapy;Zeiser;N Engl J Med,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cisplatin as a Viable and Secure Alternative to Carmustine in BEAM-Based Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma;Transplantation Proceedings;2024-07

2. Study of Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation;Advances in Clinical Medicine;2023

3. Graft-versus-host disease: Therapeutic prospects of improving the long-term post-transplant outcomes;Transplantation Reports;2022-12

4. Treatment effectiveness in a rare oncology indication: Lessons from an external control cohort study;Clinical and Translational Science;2022-06-11

5. Clinical Outcomes of Fludarabine and Melphalan With an 800 cGy Total Body Irradiation Conditioning Regimen in Patients With Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation;Clinical Lymphoma Myeloma and Leukemia;2019-06